Background: Oral anticancer agents (OAAs) medication errors can lead to significant morbidity and mortality. With the increasing number of OAAs and regimen complexity, pharmacists are instrumental in improving patient outcomes. Michigan Oncology Quality Consortium and Michigan Institute for Care Management and Transformation created the Pharmacists Optimizing Oncology Care Excellence in Michigan (POEM) initiative, whose purpose is to improve oncology patient outcomes across Michigan. POEM positions were implemented within the established Oral Chemotherapy Management Program (OCMP) at Henry Ford Health (HFH) in 2021.
Objective: This retrospective study aims to characterize the impact of POEM in the management of patients receiving OAAs at HFH.
Methods: This is a single institution, dual-site, retrospective review and analysis, to be completed at Henry Ford Medical Center – Columbus and Henry Ford Cancer – Macomb in Michigan. Study data will be collected through the electronic medical record and REDCap™ for patients enrolled into OCMP between 12/1/2021 through 11/30/2023, which will be compared to a subset of patients enrolled into OCMP before POEM implementation. Up to 200 patients with an encounter completed by a POEM pharmacist at either HFH site will be included post-implementation. Interventions will be characterized based on overall number, type, impact, and where in the point-of-care the intervention was made (prescribing, follow-up, consult). Patient baseline characteristics will be summarized to include for the post-implementation group: age, biological sex, cancer type, OAAs, overall number of medications, comorbidity score based on Charlson Comorbidity Index and National Institute of Health-National Cancer Institute Comorbidity Index, and performance status. Study results will be utilized to evaluate pharmacist interventions and to perform a gap analysis.
Results: Research in progress.
Discussion/
Conclusions: Research in progress.
References (must also be included in final poster): 1. Farris KB, Cadwallader T, Farley J, Gatwood K, Mackler E, Gatwood J. Implementation of a model integrating primary and oncology pharmacists' care for patients taking oral anticancer agents (OAA). Explor Res Clin Soc Pharm. 2022;7:100163. Published 2022 Jul 29. doi:10.1016/j.rcsop.2022.100163. 2. Soggee J, Hunt M, O'Callaghan B, et al. Specialist pharmacist consultations with cancer patients in a pharmacist-led anticancer clinic. Asia Pac J Clin Oncol. 2023;19(4):507-516. doi:10.1111/ajco.13887Sanfilippo KM, Luo S, Wang T, et al. Predicting Venous Thromboembolism in Multiple Myeloma: Development and Validation of the IMPEDE VTE Score. Am J Hematol. 2016; 94(11): 1176-1184. 3. Nhean S, Kostoff D, Yang JJ, Vogel V, Rybkin II. Impact of oral chemotherapy management program on capecitabine toxicity management. JCO Oncol Pract. 2021;17(7):e1021-e1029. doi:10.1200/OP.20.00947.
